2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 663

Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Abstract Number: 617

Peripheral Involvement Is Associated with Less Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort
Abstract Number: 671

Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
Abstract Number: 2870

Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response
Abstract Number: 1396

Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
Abstract Number: 1505

Persistence with Etanercept in Patients with Ankylosing Spondylitis or Psoriatic Arthritis in Germany: A Real-World Analysis
Abstract Number: 1602

Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus
Abstract Number: 451

Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores
Abstract Number: 1572

Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors
Abstract Number: 1728

Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus
Abstract Number: 114

Persistent Synovial Resident Memory T Cells Mediate Arthritis Flares
Abstract Number: 2278

Perspectives About Contraception Among Reproductive-Aged Women with Rheumatic Diseases
Abstract Number: 2277

Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists
Abstract Number: 2860

Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
Abstract Number: 2671

PET/CT Vascular Findings at Baseline and Six Months in Patients with Newly Diagnosed Giant Cell Arteritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].